Increased F-18 FDG intestinal uptake in diabetic patients on metformin: A matched case-control analysis

Clinical Nuclear Medicine

Volumn 36, Issue 6, 2011, Pages 452-456

  Bybel, Bohdan ^a   Greenberg, I David ^a   Paterson, Judy ^a   Ducharme, Jaylene ^a   Leslie, William D ^b  

^a HEALTH SCIENCES CENTRE   (Canada)

^b ST BONIFACE GENERAL HOSPITAL   (Canada)

Author keywords

bowel uptake; diabetic; F 18 FDG; metformin; PET CT

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE; INSULIN; METFORMIN;

ADULT; AGED; ARTICLE; BODY FAT; BODY HEIGHT; BODY MASS; BODY WEIGHT; CASE CONTROL STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DRUG ACCUMULATION; DRUG UPTAKE; ESOPHAGUS; FEMALE; GASTROINTESTINAL TRACT; GENDER; GLUCOSE BLOOD LEVEL; GLUTEUS MAXIMUS MUSCLE; HEART; HUMAN; IMAGE QUALITY; INSULIN TREATMENT; LARGE INTESTINE; LIVER; LOW CARBOHYDRATE DIET; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE ANALYSIS; RECTUM; SMALL INTESTINE; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; STOMACH; THREE DIMENSIONAL IMAGING;

ADULT; BIOLOGICAL TRANSPORT; CASE-CONTROL STUDIES; DIABETES MELLITUS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; INTESTINES; MALE; METFORMIN; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 79955809391     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e318217399e     Document Type: Article

References (24)

1. Gontier E, Fourme E, Wartski M, et al. High and typical 18F-FDG bowel uptake in patients treated with metformin. Eur J Nucl Med Mol Imag. 2008;35:95-99. (Pubitemid 350234148)
2. Ozulker T, Ozulker F, Mert M, et al. Clearance of the high intestinal 18F-FDG uptake associated with metformin after stopping the drug. Eur J Nucl Med Mol Imag. 2010;37:1011-1017.
3. Sugawara Y, Zasadny KR, Neuhoff AW, Wahl RL. Reevaluation of the standardized uptake value for FDG: variations with body weight and methods for correction. Radiology. 1999;213:521-525. (Pubitemid 29510601)
4. Bischof Delaloye A, Wahl RL. How high a level of FDG abdominal activity is considered normal? [abstract]. J Nucl Med. 1995;36(suppl):106P.
5. Nakada K, Fisher SJ, Brown RS, et al. FDG uptake in the gastrointestinal tract: can it be reduced? J Nucl Med. 1999;40:22-23.
6. Kim S, Chung JK, Kim BT, et al. Relationship between gastrointestinal F-18-fluorodeoxyglucose accumulation and gastrointestinal symptoms in whole-body PET. Clin Positron Imag. 1999;2:273-279.
7. Stahl A, Weber WA, Avril N, et al. Effect of N-butylscopolamine on intestinal uptake of fluorine-18- fluorodeoxyglucose in PET imaging of the abdomen. Nuklearmedizin. 2000;39:241-245. (Pubitemid 32039700)
8. Jadvar H, Schambye RB, Segall GM. Effect of atropine and sincalide on the intestinal uptake of F-18 fluorodeoxyglucose. Clin Nucl Med. 1999;24:965-967.
9. Miraldi F, Vesselle H, Faulhaber PF, et al. Elimination of artifactual accumulation of FDG in PET imaging of colorectal cancer. Clin Nucl Med. 1998;23:3-7. (Pubitemid 28069052)
10. Bailey CJ, Mynett KJ, Page T. Importance of the intestine as a site of metformin-stimulated glucose utilization. Br J Pharmacol. 1994;112:671-675. (Pubitemid 24172918)
11. Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334:574-579. (Pubitemid 126537875)
12. Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs. 2005;65:385-411. (Pubitemid 40227460)
13. Bailey CJ, Wilcock C, Day C. Effect of metformin on glucose metabolism in the splanchnic bed. Br J Pharmacol. 1992;105:1009-1013.
14. Ikeda T, Iwata K, Murakami H. Inhibitory effect of metformin on intestinal glucose absorption in the perfused rat intestine. Biochem Pharmacol. 2000; 59:887-890. (Pubitemid 30081713)
15. Wilcock C, Bailey CJ. Sites of metformin-stimulated glucose metabolism. Biochem Pharmacol. 1990;39:1831-1834. (Pubitemid 20166641)
16. Wilcock C, Bailey CJ. Reconsideration of inhibitory effect of metformin on intestinal glucose absorption. J Pharm Pharmacol. 1991;43:120-121.
17. Wilcock C, Bailey CJ. Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica. 1994;24:49-57. (Pubitemid 24058005)
18. Pénicaud L, Hitier Y, Ferré P, et al. Hypoglycaemic effect of metformin in genetically obese (fa/fa) rats results from an increased utilization of blood glucose by intestine. Biochem J. 1989;262:881-885. (Pubitemid 19225163)
19. Bailey CJ, Wilcock C, Scarpello JH. Metformin and the intestine. Diabeto-logia. 2008;51:1552-1553.
20. Zou MH, Kirkpatrick SS, Davis BJ, et al. Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo. Role of mitochon-drial reactive nitrogen species. J Biol Chem. 2004;279:43940-43951. (Pubitemid 39390702)
21. Walker J, Jijon HB, Diaz H, et al. 5-aminoimidazole-4-carboxamide riboside (AICAR) enhances GLUT2-dependent jejunal glucose transport: a possible role for AMPK. Biochem J. 2005;385:485-491. (Pubitemid 40173969)
22. Wang W, Guan KL. AMP-activated protein kinase and cancer. Acta Physiol (Oxf). 2009;196:55-63.
23. Sanz P. AMP-activated protein kinase: structure and regulation. Curr Protein Pept Sci. 2008;9:478-492.
24. Santomauro Júnior AC, Ugolini MR, Santomauro AT, et al. Metformin and AMPK: an old drug and a new enzyme in the context of metabolic syndrome. Arq Bras Endocrinol Metabol. 2008;52:120-125.